Dipeptidyl peptidase-4 (DPP-4) inhibitors have gained widespread importance as effective antidiabetic drugs in the management of patients with type 2 diabetes mellitus (T2DM). DPP-4 inhibitors stimulate insulin and inhibit glucagon secretion by elevating endogenous glucagon-like peptide 1 concentrations without an intrinsic hypoglycemia risk. In addition to the efficacy, these drugs have demonstrated a favorable safety profile, especially cardiovascular and renal safety. This has highlighted additional interest in the potential use of DPP-4 inhibitors in the management of T2DM. 1 In this regard, Boehringer Ingelheim India and Docplexus have organized a Multi-specialty Panel discussion on 10 th September 2020 from 03:00 PM IST.
In this webinar, an expert panel of Dr. Venkatraman S , Dr. JPS Sawhney , and Dr. Manisha Sahay will share their insights on broadening outlook with…
